Company Overview
Cassava Sciences Inc operates within the healthcare sector as a biotechnology company dedicated to developing drugs for neurodegenerative diseases. The firm focuses on creating therapeutic and diagnostic solutions, with its lead therapeutic product candidate, simufilam, being a small molecule drug that has completed Phase 2 clinical trials, alongside an investigational diagnostic product candidate known as SavaDx. The company maintains a market capitalization of $114.97M and employs 30 individuals to execute its clinical stage biotechnology strategy. These valuation and staffing figures indicate that Cassava Sciences Inc is a small-cap entity with a relatively lean operational footprint, positioning it within the early-to-mid stage of biotechnology development where capital efficiency and clinical milestones are primary drivers of value rather than established commercial revenue streams.
Financial Health
The company reports net income (TTM) of $-106,031,000 and EBITDA of $-69,296,000, while annual revenue (TTM) is not available in the provided data. The significant gap between the negative net income and the less negative EBITDA suggests that interest, taxes, depreciation, and amortization expenses, along with non-operating costs, contribute substantially to the bottom-line loss, which is typical for clinical-stage biotechnology firms with high burn rates. Despite the negative earnings, the company generates free cash flow of $18.57M, indicating a degree of financial flexibility that allows for continued research and development activities without immediate reliance on external equity financing. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting that the company has not yet achieved commercial profitability and is currently operating in a pre-revenue or early commercialization phase where costs exceed revenues. The balance sheet holds $106.08M in cash against N/A in debt, resulting in a debt-to-equity ratio of N/A, which points to a conservative capital structure reliant on equity rather than leverage. Additionally, the current ratio stands at 2.27, signaling strong short-term liquidity that provides a robust buffer against operational expenses and potential clinical trial costs. The return on equity is -85.4% and the return on assets is -24.8%, metrics that reveal management is currently deploying capital to generate negative returns as the company invests heavily in pipeline development before reaching a sustainable commercial break-even point.
Valuation Assessment
The trailing P/E ratio is listed as N/A due to the negative earnings, whereas the forward P/E is -1.34, a figure that implies the market is pricing in a potential turnaround or that earnings are expected to remain negative in the near future. The price-to-book ratio is 1.41, indicating that the market values the company at 41% above its book value, which suggests a premium placed on the intellectual property and clinical pipeline despite the lack of current profits. The price-to-sales ratio is N/A, and the EV/EBITDA is 0.07, suggesting an extremely low multiple based on earnings before interest, taxes, depreciation, and amortization that reflects the company's current loss-making status. The stock has a 52-week high of $4.98 and a 52-week low of $1.15; without a specific current price provided in the facts, the valuation range indicates a high degree of volatility with a trading band of approximately $3.83. The beta is -0.84, which is highly unusual for equities and implies an inverse correlation to the broader market, meaning the stock tends to move in the opposite direction of the market index with a magnitude of 0.84 times the market's volatility.
Growth & Income
Revenue growth (YoY) and earnings growth (YoY) are both listed as N/A, preventing a direct calculation of growth rates but highlighting the challenges in quantifying expansion for a company with limited historical financial data. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all generated cash and equity capital are reinvested into the business to fund clinical trials and operational expansion rather than distributed to shareholders. This reinvestment strategy is standard for biotechnology firms that prioritize pipeline advancement over immediate income generation for investors. Consequently, the overall growth and income profile is characterized by a complete focus on capital allocation toward clinical milestones and asset development, with no current reliance on dividend income or predictable historical growth rates to assess performance.